Pterostilbene Clinical Trials

Size	Price	Qty
25mg	USD 147
1g	USD 1,970

Clinical Trials

Multiple clinical trials evaluate pterostilbene across Phase 1 safety evaluations to Phase 2 and Phase 3 efficacy studies targeting metabolic, neurological, renal, and oncological conditions, including hyperlipidemia, acute kidney injury, amyotrophic lateral sclerosis, and endometrial carcinoma. Sponsored by academic institutions, health systems, and industry partners, this body of research encompasses a mix of completed, active, and recruiting protocols.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07579429	RECRUITING	Clonal Cytopenia of Undetermined Significance; Myelodysplastic Syndrome	University of Colorado, Denver	2026-05-20	PHASE2
NCT04562831	ACTIVE_NOT_RECRUITING	Amyotrophic Lateral Sclerosis	Haukeland University Hospital	2020-10-07
NCT05095571	RECRUITING	Amyotrophic Lateral Sclerosis	Haukeland University Hospital	2021-10-07
NCT07024966	RECRUITING	Oxidative Stress; Physical Activity; Antioxidant Effect	Fundació Eurecat	2025-08-01
NCT06289140	COMPLETED	Biological Availability	Fundació Eurecat	2024-03-11
NCT04342975	COMPLETED	AKI	Mayo Clinic	2020-12-01	PHASE2
NCT03671811	ACTIVE_NOT_RECRUITING	Atypical Endometrial Hyperplasia; Endometrial Carcinoma	City of Hope Medical Center	2019-01-21	PHASE2
NCT05561075	COMPLETED	Biological Availability	Fundació Eurecat	2022-10-20
NCT04841499	COMPLETED	Menopause	University of South Alabama	2021-04-05
NCT03635411	UNKNOWN	Recovery of Function	Elysium Health	2018-12-06	PHASE1
NCT03754842	COMPLETED	Muscle Injury	University of Aarhus	2019-02-12
NCT03176628	COMPLETED	Acute Kidney Injury	Massachusetts General Hospital	2017-11-01
NCT03176628	Completed	Acute Kidney Injury	Massachusetts General Hospital\|Elysium Health	2017-11-01	Not Applicable
NCT01267227	COMPLETED	Hyperlipidemia; Blood Pressure; Oxidative Stress	University of Mississippi Medical Center	2010-12	PHASE2; PHASE3

(data from https://clinicaltrials.gov, updated on 2026-06-03)

Check the Pterostilbene product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Pterostilbene functions as a lipophilic stilbenoid that activates sirtuin 1 and peroxisome proliferator-activated receptor alpha while scavenging reactive oxygen species, thereby suppressing nuclear factor-kappa B signaling and modulating downstream inflammatory cascades. This molecular action attenuates cellular oxidative damage and pro-inflammatory cytokine release, supporting its potential therapeutic utility in trial-studied conditions including acute kidney injury, hyperlipidemia, and amyotrophic lateral sclerosis.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).